Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma

Affiliations

Editorial

Jesper B Andersen. Hepatology. 2022 Nov.

. 2022 Nov;76(5):1233-1236.

doi: 10.1002/hep.32558. Epub 2022 Jun 6.

¹ Biotech Research and Innovation Center, Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

No abstract available

Comment on

Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
Wang T, Xu C, Zhang Z, Wu H, Li X, Zhang Y, Deng N, Dang N, Tang G, Yang X, Shi B, Li Z, Li L, Ye K. Wang T, et al. Hepatology. 2022 Nov;76(5):1302-1317. doi: 10.1002/hep.32483. Epub 2022 Apr 24. Hepatology. 2022. PMID: 35340039 Free PMC article.

1. Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology. 2018;68(3):949-63.
1. O'Rourke CJ, Lafuente-Barquero J, Andersen JB. Epigenome remodeling in cholangiocarcinoma. Trends Cancer. 2019;5(6):335-50.
1. Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116-35.
1. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142(4):1021-31.e1015.
1. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829-40.